Molecular profiling assays in breast cancer: are we ready for prime time?
Breast cancer is a heterogeneous disease with diverse morphologies, molecular characteristics, and clinical behavior. The advances in molecular profiling technologies have changed our understanding of breast cancer and led to the identification of prognostic/predictive gene signatures. Despite the huge quantity of information gleaned from these profiling technologies and the increasing number of gene signatures, their incorporation into clinical decision making is a slow process and is limited in various aspects. The 70-gene assay (MammaPrint, Agendia, Netherlands) and the 21-gene assay (Oncotype DX, Genomic Health, USA) are the most widely used breast cancer multigene classifier assays. A 50-gene assay (PAM50, NanoString, USA) has shown promise but needs further independent validation. In this review, we will present the current data on commercially available molecular profiling assays in breast cancer and discuss the challenges surrounding their incorporation into routine clinical practice as prognostic and predictive tools.
Department of Medicine, Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
SourceOncology (Williston Park, N.Y.) 26:4 2012 Apr pg 350-7, 361
Gene Expression Profiling
Practice Guidelines as Topic
Pub Type(s)Journal Article